Molecular mechanisms and intervention approaches of heart failure (Review)

Shuang Guo1, Yingqing Hu2, Li Ling2

  • 1Hubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China.

Insights

Heart failure, a complex condition, arises from various cardiovascular diseases. This review explores its molecular mechanisms, offering insights into prevention and treatment strategies.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pathophysiology

Background:

  • Heart failure is a critical health concern, often representing the end stage of conditions like arrhythmia and myocardial infarction.
  • Cardiovascular diseases contribute to heart failure through mechanisms including myocardial fibrosis, cell death, and impaired mitochondrial function.
  • The intricate molecular pathways of heart failure are not fully understood, limiting effective interventions.

Purpose of the Study:

  • To review recent advancements in understanding heart failure.
  • To elucidate the complex molecular mechanisms underlying heart failure.
  • To provide evidence-based strategies for heart failure prevention and treatment.

Main Methods:

  • Comprehensive literature review of recent research on heart failure.
  • Analysis of pathological mechanisms contributing to heart failure.
  • Synthesis of current knowledge on molecular pathways involved in heart failure.

Main Results:

  • Identified key pathological mechanisms: myocardial fibrosis, hypertrophy, cell death, mitochondrial dysfunction, vascular remodeling, and calcium dysregulation.
  • Highlighted the complexity and elusiveness of detailed molecular mechanisms.
  • Compiled a review of current research progress.

Conclusions:

  • Understanding the molecular basis of heart failure is crucial for developing effective treatments.
  • Further research into these complex mechanisms is needed.
  • This review provides a foundation for future prevention and intervention strategies for heart failure.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
350
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
321
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
543
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
611